Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome

Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome

The present literature review provides evidence that in patients with low-risk myelodysplastic syndrome and transfusion dependence blood parameters and survival rates can be improved by administration of iron chelators. Dose adequacy and therapy duration underlie clinical efficacy of chelators. Toxi...

Full description

Bibliographic Details
Main Authors: SV Gritsaev, II Kostroma, AA Zhernyakova
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2019-03-01
Series:Kliničeskaâ onkogematologiâ
Subjects:
myelodysplastic syndrome
low risk
transfusion dependence
iron chelators
survival
Online Access: http://bloodjournal.ru/wp-content/uploads/2019/03/2-6.pdf
id doaj-dce23ab0da454579b5a9571d47796d3d
record_format Article
spelling doaj-dce23ab0da454579b5a9571d47796d3d2020-11-25T02:24:33ZrusPractical Medicine Publishing HouseKliničeskaâ onkogematologiâ1997-69332500-21392019-03-0112212012410.21320/2500-2139-2019-12-2-120-12419976933Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic SyndromeSV Gritsaev0II Kostroma1AA Zhernyakova2 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 The present literature review provides evidence that in patients with low-risk myelodysplastic syndrome and transfusion dependence blood parameters and survival rates can be improved by administration of iron chelators. Dose adequacy and therapy duration underlie clinical efficacy of chelators. Toxicity can be reduced by administrating a new formula of deferasirox that does not need to be dissolved in liquid before consuming. http://bloodjournal.ru/wp-content/uploads/2019/03/2-6.pdf myelodysplastic syndromelow risktransfusion dependenceiron chelatorssurvival
collection DOAJ
language Russian
format Article
sources DOAJ
author SV Gritsaev
II Kostroma
AA Zhernyakova
spellingShingle SV Gritsaev
II Kostroma
AA Zhernyakova
Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
Kliničeskaâ onkogematologiâ
myelodysplastic syndrome
low risk
transfusion dependence
iron chelators
survival
author_facet SV Gritsaev
II Kostroma
AA Zhernyakova
author_sort SV Gritsaev
title Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
title_short Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
title_full Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
title_fullStr Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
title_full_unstemmed Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
title_sort clinical efficacy of chelation therapy in patients with low-risk myelodysplastic syndrome
publisher Practical Medicine Publishing House
series Kliničeskaâ onkogematologiâ
issn 1997-6933
2500-2139
publishDate 2019-03-01
description The present literature review provides evidence that in patients with low-risk myelodysplastic syndrome and transfusion dependence blood parameters and survival rates can be improved by administration of iron chelators. Dose adequacy and therapy duration underlie clinical efficacy of chelators. Toxicity can be reduced by administrating a new formula of deferasirox that does not need to be dissolved in liquid before consuming.
topic myelodysplastic syndrome
low risk
transfusion dependence
iron chelators
survival
url http://bloodjournal.ru/wp-content/uploads/2019/03/2-6.pdf
work_keys_str_mv AT svgritsaev clinicalefficacyofchelationtherapyinpatientswithlowriskmyelodysplasticsyndrome
AT iikostroma clinicalefficacyofchelationtherapyinpatientswithlowriskmyelodysplasticsyndrome
AT aazhernyakova clinicalefficacyofchelationtherapyinpatientswithlowriskmyelodysplasticsyndrome
_version_ 1724855046741426176

Similar Items